Search
forLearn
5 / 801 resultslearn Dihydroquercetin-glucoside
learn Quercetin
learn Ubiquinone
learn oleanolic acid
Research
5 / 191 results
research Hair growth promoting effects of emodin in telogenic C57BL/6 mice
Emodin may help hair grow similarly to minoxidil and could treat baldness.
research Medicinal Plants and their Constituents in the Treatment of Acne vulgaris
Medicinal plants may be an effective alternative for treating acne.
research A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
research Aloe Vera Gel Effect on Skin and Pharmacological Properties
Aloe Vera gel helps heal skin, treats skin conditions, and can stimulate hair growth due to its various healing properties.
research The green healer: an updated review on the phytochemical profile and therapeutic potential of Aloe vera
Aloe vera is effective for healing, skin, and health due to its beneficial compounds.
Community Join
5 / 1000+ resultscommunity AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.